All stock lists
Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
Healthcare · Biotechnology
7.90-0.13 (-1.62%)
Insider Score
––Not scored
CADL Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
CADL analyst forecast
CADL analyst consensus
Moderate Buy2 ratings
Buy 2 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
CADL 12-month price target
$25.00+216.5% upsideaverage of 1 firm
$25.00High
$25.00Low
Best analysts covering CADL
- HC Wainwright & Co.44%success rate · 9 calls
- Canaccord Genuity0%success rate · 1 call
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
CADL analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| Jefferies | — | $25.00 | +198.7% | — | 2026-10-22 | |
| — | B of A Securities | Buy | — | — | Upgraded | 2026-09-21 |
| — | B of A Securities | Neutral | — | — | Reiterated | 2026-08-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-13 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-03-18 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-03-13 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-03-13 |
| — | Stephens & Co. | Overweight | — | — | Reiterated | 2025-12-08 |
| — | Freedom Broker | Buy | — | — | Reiterated | 2025-11-21 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-11-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-09-29 |
| — | B of A Securities | Neutral | — | — | Downgraded | 2025-09-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-14 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-02-26 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-02-26 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-11-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-05-22 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2023-05-15 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2023-03-31 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2022-12-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2022-12-02 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2022-09-02 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2022-03-31 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2021-11-19 |
| — | Credit Suisse | Outperform | — | — | Reiterated | 2021-08-23 |
| — | UBS | Buy | — | — | Reiterated | 2021-08-23 |
| — | Jefferies | Buy | — | — | Reiterated | 2021-08-23 |
CADL earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-12 | -0.24 | -0.54 | $0 | $0 |
| 2026-05-14 | -0.22 | -0.14 | $0 | $0 |
| 2026-08-13 | -0.24 | -0.52 | $0 | $0 |
| 2026-11-12 | -0.35 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.